Welcome to our dedicated page for NMDBF news (Ticker: NMDBF), a resource for investors and traders seeking the latest updates and insights on NMDBF stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect NMDBF's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of NMDBF's position in the market.
NeonMind Biosciences Inc. (CSE:NEON)(OTCQB:NMDBF) announced positive preclinical data showing psilocybin's efficacy in reducing weight gain in obese subjects. The study demonstrated statistically significant results in both absolute and relative weight gain, with notable reductions in food consumption and no safety concerns. This reinforces the potential of NeonMind's psilocybin-based drug candidates, NEO-001 and NEO-002, aimed at obesity treatment. The findings support further development and highlight the ability to target visceral fat, crucial for improving cardiometabolic health.
NeonMind Biosciences Inc. (OTCQB: NMDBF) has filed a new provisional patent with the U.S. Patent and Trademark Office for a novel weight loss mechanism targeting specific fat types. This application is based on promising findings from a preclinical animal study that shows potential benefits for metabolic and cardiovascular health via psilocybin's effects. If approved, the patent could protect its pharmaceutical assets until 2042. NeonMind is developing two drug candidates, NEO-001 and NEO-002, aimed at treating obesity through psilocybin-induced neuropharmacological changes and appetite control.
NeonMind Biosciences has achieved significant milestones in its strategy as a leader in psychedelic drug development and specialty clinics operation. The company is advancing its psilocybin-based obesity treatment, NEO-001, with expectations to initiate Phase 1/2 clinical studies this year after completing a pre-IND consultation with the FDA. Additionally, partnerships with SRx Health Solutions and BioScript Solutions will establish NeonMind-branded mental health clinics across Canada. The company is well-positioned for growth in the expanding psychedelic industry.
NeonMind Biosciences (OTCQB:NMDBF) has announced a strategic partnership with BioScript Solutions to expand access to its interventional psychiatry programs in Canada. This collaboration will utilize BioScript's extensive network of over 100 infusion clinics to enhance patient care for mental health and obesity treatments. NeonMind plans to identify and launch its first clinic location in early 2022, with ambitions for further expansion throughout the year. The partnership aims to address the growing mental health crisis and improve access to specialty care for Canadians.
NeonMind Biosciences Inc. (OTCQB:NMDBF) has appointed Dr. Daniel Bainbridge, a prominent anesthesiologist and past president of the Canadian Anesthesiologists Society, to its Specialty Clinics Advisory Board. This move aims to enhance the safety protocols for administering intravenous ketamine (IV-ketamine) in specialty clinics, which provide treatments for mood and anxiety disorders. Dr. Bainbridge's expertise will help assure best-in-class practices in patient care. His involvement is expected to improve access to IV-ketamine as part of NeonMind's commitment to addressing the mental health crisis.
NeonMind Biosciences Inc. (OTCQB: NMDBF) announced its participation in the H.C. Wainwright Bioconnect Conference, scheduled for January 10-13, 2022. CEO Robert Tessarolo will present, with the presentation available on-demand starting January 10 at 7:00 a.m. ET. NeonMind operates a pharmaceutical division developing psilocybin-based treatments aimed at addressing obesity and a medical services division focused on mental health clinics. More details can be found by contacting KCSA Strategic Communications or visiting NeonMind's website.
NeonMind Biosciences Inc. (OTCQB: NMDBF) announced its participation in the H.C. Wainwright 2nd Annual Psychedelics Conference on December 6, 2021. CEO Robert Tessarolo will present, with the presentation available on-demand starting at 7:00 a.m. ET. NeonMind focuses on the therapeutic uses of psilocybin for treating obesity, with two lead drug candidates: NEO-001 and NEO-002. Additionally, the company plans to launch specialty mental health clinics in Canada to integrate psychedelic treatments into psychotherapy.
NeonMind Biosciences Inc. announced a successful pre-Investigational New Drug (IND) consultation with the FDA for its obesity drug candidate, NEO-001. This marks a significant step toward initiating a Phase 1/2 clinical study in H1 2022. The FDA validated NeonMind's clinical approach and provided constructive feedback, which the company will incorporate without altering the development timeline. NEO-001 combines high-dose psilocybin treatment with behavioral therapy aimed at sustainable weight management. This positions NeonMind to lead in psychedelic-based treatments for obesity.
NeonMind Biosciences Inc. (CSE:NEON, OTCQB:NMDBF) is set to participate in the Psychedelics Business Summit at the Lift & Co. Expo on November 19, 2021, in Toronto. CEO Rob Tessarolo will join a panel discussing strategies that benefit both patients and investors. The event aims to provide insights into psychedelics research, legislation, and investment opportunities. NeonMind focuses on developing psilocybin-based drugs targeting obesity and plans to launch mental health clinics integrating psychedelic therapies.
FAQ
What is the market cap of NMDBF (NMDBF)?
